BioCentury | Feb 22, 2021
Management Tracks

Fresh from $21B Gilead deal, Immunomedics vet Malik to lead newly rebranded precision medicines company Fore

...rights to the BRAF program from the Plexxikon...
BioCentury | Sep 22, 2020
Finance

Sept. 21 Quick Takes: venture funding for Novellus, Immune Regulation, XWPharma and CoreMap

...a BRAF inhibitor that the Israeli biotech licensed from Daiichi Sankyo Co. Ltd. (Tokyo:4568) subsidiary Plexxikon...
BioCentury | May 24, 2019
Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

...therapeutic area the focus of its future growth. Pexidartinib came from Daiichi’s 2011 takeout of Plexxikon Inc....
BioCentury | Oct 27, 2017
Company News

Daiichi and MD Anderson partner to develop AML candidates

...testing to treat solid tumors and hematologic malignancies. Daiichi obtained its rights when it acquired Plexxikon Inc....
BioCentury | Dec 2, 2015
Company News

Management tracks

...Calif). named Prabha Ibrahim CTO. She was SVP of chemistry and non-clinical development at the Plexxikon Inc....
BioCentury | Nov 9, 2015
Product Development

TRK or treat baskets

...two other clinical-stage programs target TRK for cancer: PLX7486 from Daiichi Sankyo Co. Ltd .'s Plexxikon Inc....
...CD115 ) and TrkA, TrkB and TrkC that is in a dose-escalation Phase I. Plexxikon...
BioCentury | Jul 13, 2015
Company News

Daiichi Sankyo, Merck deal

...Daiichi’s Plexxikon Inc. subsidiary and Merck partnered to evaluate Plexxikon’s PLX3397 and Merck’s melanoma drug Keytruda pembrolizumab...
BioCentury | Feb 20, 2015
Company News

Genentech's cobimetinib NDA gets Priority Review

...its option to co-promote the compound in the U.S. Roche has rights to Zelboraf from Plexxikon Inc....
BioCentury | Dec 16, 2014
Company News

Genentech submits NDA for melanoma combo

...its option to co-promote the compound in the U.S. Roche has rights to Zelboraf from Plexxikon Inc....
BioCentury | Dec 15, 2014
Clinical News

PLX3397: Phase II start

...Daiichi Sankyo’s Plexxikon Inc. subsidiary said PLX3397 will join the ongoing Phase II I-SPY 2 trial in...
Items per page:
1 - 10 of 206
BioCentury | Feb 22, 2021
Management Tracks

Fresh from $21B Gilead deal, Immunomedics vet Malik to lead newly rebranded precision medicines company Fore

...rights to the BRAF program from the Plexxikon...
BioCentury | Sep 22, 2020
Finance

Sept. 21 Quick Takes: venture funding for Novellus, Immune Regulation, XWPharma and CoreMap

...a BRAF inhibitor that the Israeli biotech licensed from Daiichi Sankyo Co. Ltd. (Tokyo:4568) subsidiary Plexxikon...
BioCentury | May 24, 2019
Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

...therapeutic area the focus of its future growth. Pexidartinib came from Daiichi’s 2011 takeout of Plexxikon Inc....
BioCentury | Oct 27, 2017
Company News

Daiichi and MD Anderson partner to develop AML candidates

...testing to treat solid tumors and hematologic malignancies. Daiichi obtained its rights when it acquired Plexxikon Inc....
BioCentury | Dec 2, 2015
Company News

Management tracks

...Calif). named Prabha Ibrahim CTO. She was SVP of chemistry and non-clinical development at the Plexxikon Inc....
BioCentury | Nov 9, 2015
Product Development

TRK or treat baskets

...two other clinical-stage programs target TRK for cancer: PLX7486 from Daiichi Sankyo Co. Ltd .'s Plexxikon Inc....
...CD115 ) and TrkA, TrkB and TrkC that is in a dose-escalation Phase I. Plexxikon...
BioCentury | Jul 13, 2015
Company News

Daiichi Sankyo, Merck deal

...Daiichi’s Plexxikon Inc. subsidiary and Merck partnered to evaluate Plexxikon’s PLX3397 and Merck’s melanoma drug Keytruda pembrolizumab...
BioCentury | Feb 20, 2015
Company News

Genentech's cobimetinib NDA gets Priority Review

...its option to co-promote the compound in the U.S. Roche has rights to Zelboraf from Plexxikon Inc....
BioCentury | Dec 16, 2014
Company News

Genentech submits NDA for melanoma combo

...its option to co-promote the compound in the U.S. Roche has rights to Zelboraf from Plexxikon Inc....
BioCentury | Dec 15, 2014
Clinical News

PLX3397: Phase II start

...Daiichi Sankyo’s Plexxikon Inc. subsidiary said PLX3397 will join the ongoing Phase II I-SPY 2 trial in...
Items per page:
1 - 10 of 206